Fred Saad

Summary

Country: Canada

Publications

  1. ncbi A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 94:1458-68. 2002
  2. ncbi The role of bisphosphonates in the management of prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Curr Oncol Rep 8:221-7. 2006
  3. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    BJU Int 96:964-9. 2005
  4. ncbi The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Division of Urology, Department of Surgery, Centre Hospitalier de l Universite de Montreal, Montreal, PQ H2L 4M1 Quebec, 1560 Rue Sherbrooke East, Canada
    World J Urol 23:14-8. 2005
  5. ncbi The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel
    Fred Saad
    Universite de Montreal, Quebec, Canada
    Clin Genitourin Cancer 4:257-62. 2006
  6. ncbi Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, QC, Canada
    Nat Clin Pract Urol 4:S3-13. 2007
  7. ncbi Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urol Oncol 24:4-12. 2006
  8. ncbi Natural history and treatment of bone complications in prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Eur Urol 49:429-40. 2006
  9. ncbi Bone-directed treatments for prostate cancer
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hospital Notre Dame, Department of Surgery Urology, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Hematol Oncol Clin North Am 20:947-63. 2006
  10. ncbi Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Eur Urol 46:731-39; discussion 739-40. 2004

Detail Information

Publications109 found, 100 shown here

  1. ncbi A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 94:1458-68. 2002
    ..We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases...
  2. ncbi The role of bisphosphonates in the management of prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Curr Oncol Rep 8:221-7. 2006
    ..Therefore, bisphosphonates, particularly zoledronic acid, may provide important benefits for preserving bone health during the course of prostate cancer progression...
  3. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    BJU Int 96:964-9. 2005
    ..In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use...
  4. ncbi The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Division of Urology, Department of Surgery, Centre Hospitalier de l Universite de Montreal, Montreal, PQ H2L 4M1 Quebec, 1560 Rue Sherbrooke East, Canada
    World J Urol 23:14-8. 2005
    ..Therefore, initiation of zoledronic acid therapy should be considered to prevent skeletal morbidity and improve the quality of life of these patients...
  5. ncbi The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel
    Fred Saad
    Universite de Montreal, Quebec, Canada
    Clin Genitourin Cancer 4:257-62. 2006
    ..However, further study of the use of bisphosphonates across the clinical spectrum of prostate cancer is needed...
  6. ncbi Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, QC, Canada
    Nat Clin Pract Urol 4:S3-13. 2007
    ..The early diagnosis and treatment of bone loss and bone metastases with bisphosphonates are critical for the maintenance of skeletal wellness and prevention of bone complications in patients with prostate cancer...
  7. ncbi Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urol Oncol 24:4-12. 2006
    ..According to this algorithm, zoledronic acid should be considered for the prevention of skeletal morbidity in patients with prostate cancer throughout their treatment continuum...
  8. ncbi Natural history and treatment of bone complications in prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Eur Urol 49:429-40. 2006
    ....
  9. ncbi Bone-directed treatments for prostate cancer
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hospital Notre Dame, Department of Surgery Urology, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Hematol Oncol Clin North Am 20:947-63. 2006
    ....
  10. ncbi Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Eur Urol 46:731-39; discussion 739-40. 2004
    ....
  11. ncbi Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier, University of Montreal, Montreal, Quebec, Canada
    Clin Prostate Cancer 1:145-52. 2002
    ..Zoledronic acid is the first and only bisphosphonate shown to reduce skeletal morbidity, including fractures, in patients with advanced prostate cancer and bone metastases...
  12. doi Research in genitourinary oncology: the Canadian Uro-Oncology Group multidisciplinary model
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, University of Montreal, Canada
    BJU Int 102:7-8. 2008
  13. ncbi Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 96:879-82. 2004
    ..Long-term treatment with 4 mg of zoledronic acid is safe and provides sustained clinical benefits for men with metastatic hormone-refractory prostate cancer...
  14. doi A population based assessment of perioperative mortality after cystectomy for bladder cancer
    Hendrik Isbarn
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    J Urol 182:70-7. 2009
    ..Contemporary estimates range from 0.7% to 5.6%. We tested several predictors of perioperative mortality and devised a model for individual perioperative mortality prediction...
  15. doi Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada
    J Urol 181:601-7; discussion 607-8. 2009
    ..Identifying patients at risk for early recurrence may improve prognosis as early institution of adjuvant therapy may reduce the risk of progression...
  16. doi Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis
    Jean Simon Diallo
    Centre de recherche du Centre Hospitalier de l Université de Montréal CR CHUM, Institut du Cancer de Montreal, Quebec, Canada
    BJU Int 101:1302-9. 2008
    ....
  17. doi Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer
    Philippe O Gannon
    Centre de recherche du Centre Hospitalier de l Universite de Montreal, Institut du Cancer de Montreal, and Faculty of Medicine, Universite de Montreal, Montreal, Quebec, Canada
    Eur J Cancer 49:2441-8. 2013
    ..Our goal was to validate these results in a large independent cohort of PCa patients who underwent radical prostatectomy...
  18. ncbi Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer
    Benjamin Péant
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada H2L 4M1
    Mol Cancer Res 5:87-94. 2007
    ..To our knowledge, this is the first report of an IkappaB kinase family member whose expression is modulated by androgen and deregulated in androgen receptor-negative cells...
  19. doi The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients
    Naeem Bhojani
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Int J Radiat Oncol Biol Phys 76:342-8. 2010
    ..We tested this hypothesis in a large French Canadian population-based cohort of prostate cancer patients...
  20. ncbi Accuracy of life tables in predicting overall survival in patients after radical prostatectomy
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 102:33-8. 2008
    ....
  21. doi Radical versus partial nephrectomy: effect on overall and noncancer mortality
    Laurent Zini
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 115:1465-71. 2009
    ..Relative to radical nephrectomy (RN), partial nephrectomy (PN) performed for renal cell carcinoma (RCC) may protect from non-cancer-related deaths. The authors tested this hypothesis in a cohort of PN and RN patients...
  22. ncbi A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    J Clin Oncol 25:3576-81. 2007
    ..To circumvent this problem, we developed a nomogram predicting 10-year LE for patients treated with either radical prostatectomy (RP) or external-beam radiation therapy (EBRT) and compared it with an existing tool...
  23. ncbi High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Eur Urol 54:97-105. 2008
    ..We examined the effect of annual and cumulative provider volume on the rate of use of secondary therapies after definitive external-beam radiotherapy (EBRT) for localized prostate cancer...
  24. ncbi Prostate volume and adverse prostate cancer features: fact not artifact
    Alberto Briganti
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Canada
    Eur J Cancer 43:2669-77. 2007
    ..We investigated the association between prostate size and prostate cancer grade and stage in a large (n=3412) single center radical prostatectomy cohort, which was unexposed to any form of hormonal manipulation...
  25. ncbi Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer
    Ismael H Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    BJU Int 100:303-9. 2007
    ....
  26. ncbi Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases
    Laurent Lessard
    Centre de recherche du Centre Hospitalier de l Universite de Montreal, Institut du Cancer de Montreal, and the Department of Surgery Urology, CHUM, University of Montreal, 1560 rue Sherbrooke Est, Montreal, Quebec, Canada
    Clin Cancer Res 12:5741-5. 2006
    ..Because nuclear factor-kappaB (NF-kappaB) is a candidate marker of prostate cancer progression, we tested the association between nuclear localization of NF-kappaB in radical prostatectomy specimens and the presence of LNI...
  27. ncbi Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Eur Urol 54:107-16. 2008
    ..We examined the rate of 10-yr survival in septa- and octogenarians treated for prostate cancer with either attempted curative external beam radiotherapy (EBRT) or radical prostatectomy (RP)...
  28. ncbi Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    BJU Int 100:1254-8. 2007
    ....
  29. doi Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men
    Andrea Gallina
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Int J Cancer 123:647-52. 2008
    ..In conclusion, our data suggest that prostate biopsy might predispose to higher mortality rate. The certainty of this association remains to be proven...
  30. ncbi NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells
    Laurent Lessard
    Universite de Montreal, Centre de recherche du CHUM et Institut du cancer de Montréal, 1560 Sherbrooke East, Montreal, QC, Canada, H2L 4M1
    Cell Signal 19:1093-100. 2007
    ..These results point to a novel mechanism by which androgens regulate NF-kappaB and provide a rationale for further studies into the biological significance of non-canonical NF-kappaB signalling in prostate cancer...
  31. pmc Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer
    Philippe O Gannon
    Centre de recherche du Centre hospitalier de l Université de Montréal CRCHUM and Institut du cancer de Montréal, Montreal, Quebec, Canada
    PLoS ONE 5:e12107. 2010
    ..Arginase 2 (ARG2) expression by PCa cells leads to a reduced activation of tumor-specific T cells. Our hypothesis was that androgens could regulate the expression of ARG2 by PCa cells...
  32. ncbi Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 69:88-94. 2007
    ..To test the accuracy of life tables (LTs) in predicting survival in men treated with radiotherapy for localized prostate cancer...
  33. doi External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy
    Shahrokh F Shariat
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    J Clin Oncol 26:1526-31. 2008
    ..However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort...
  34. doi Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
    M Dror Michaelson
    M Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA Stephane Oudard, George Pompidou European Hospital, Rene Descartes University, Paris Nadine Houede, Institut Bergonie, Bordeaux Tristan Maurina, CHU de Besancon, Hopital Jean Minjoz, Besancon, France Yen Chuan Ou, Taichung Veterans General Hospital, Taichung, Taiwan Lisa Sengeløv, Herlev Hospital, Herlev Gedske Daugaard, Rigshospitalet, Copenhagen, Denmark Fred Saad, University of Montreal, Montreal, Canada Peter Ostler, Mount Vernon Hospital, Northwood, Middlesex Robert Jones, Beatson West of Scotland Cancer Centre, Glasgow Amit Bahl, Bristol Haematology and Oncology Centre, Bristol, UK Arnulf Stenzl, Eberhard Karls University Medical School, Tübingen Juergen Gschwend, Technical University of Munich, Munich, Germany Fredrik Laestadius and Anders Ullèn, Karolinska University Hospital, Stockholm, Seoul 140-715
    J Clin Oncol 32:76-82. 2014
    ..We evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC)...
  35. ncbi The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone
    Fred Saad
    University of Montreal Hospital Centre, Montreal, PQ, Canada
    BJU Int 102:551-5. 2008
    ....
  36. ncbi Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy
    Giovanni Lughezzani
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 78:1307-13. 2010
    ....
  37. doi Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines
    Benjamin Péant
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Quebec, Canada
    Prostate 69:706-18. 2009
    ..Previous studies, in murine embryonic fibroblasts, have shown that Ikappa-B kinase-epsilon (IKKepsilon/IKKi)-deficiency results in the reduction of lipopolysaccharide-mediated expression of IL-6...
  38. ncbi NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model
    Jean Simon Diallo
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Quebec, Canada
    Clin Cancer Res 13:7044-52. 2007
    ..To assess the expression of proapoptotic NOXA and PUMA in prostate tissues and delineate their association with prostate cancer (PCa) recurrence...
  39. ncbi Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec
    Pierre I Karakiewicz
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Can J Urol 12:2588-92. 2005
    ..Moreover, we assessed the extent of change in predictive accuracy related to a modification of PSA coding from categorical to continuous...
  40. doi Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort
    Umberto Capitanio
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Urology 73:1323-7. 2009
    ..To examine the distribution of total prostate-specific antigen (tPSA) and percentage of free/total PSA (%f/tPSA) values in patients undergoing prostate cancer screening in Canada...
  41. doi A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma
    Laurent Zini
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Clin Cancer Res 15:1013-8. 2009
    ..We attempted to develop a simpler prediction rule with at least equal accuracy in predicting CSM after surgical removal of PPSCC...
  42. doi Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
    J Urol 182:626-32. 2009
    ....
  43. ncbi [NFkappaB : a new marker kappable of predicting prostate cancer outcome]
    Laurent Lessard
    Centre de recherche du CHUM et Institut du cancer de Montréal, 1560 Sherbrooke Est, Montreal, QC, Canada, H2L 4M1
    Bull Cancer 93:891-9. 2006
    ..The addition of NFkappaB and other molecular markers to current clinical markers will facilitate the identification of high risk patients and guide clinicians in the choice of an appropriate therapeutic approach...
  44. ncbi Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells
    Cécile Le Page
    Centre de recherche du Centre Hospitalier de l Université de Montréal CR CHUM, 1560 rue Sherbrooke Est, Montreal, Quebec, Canada
    Prostate 65:306-15. 2005
    ....
  45. ncbi Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening
    Georg Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 1058, rue St Denis, Montreal, Que, Canada
    Eur J Cancer 43:1180-7. 2007
    ..Body mass index (BMI) may alter serum prostate specific antigen (PSA) and percent free PSA (%fPSA) and may mask the risk of prostate cancer. We investigated the relationship between BMI and PSA or %fPSA...
  46. ncbi Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL
    Andrea Gallina
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Eur Urol 52:1374-80. 2007
    ..To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa)...
  47. ncbi An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines
    Jean Simon Diallo
    Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM and Institut du Cancer de Montréal, Montreal, Quebec, Canada
    Prostate 66:1245-56. 2006
    ..Inositol hexakisphosphate (IP6) is a phytochemical exhibiting anticancer activity. Because few prostate cancer (PCa) cell lines have been used to study IP6, we assessed its efficacy in a panel of PCa cell lines...
  48. doi Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Canada
    Expert Rev Anticancer Ther 10:1991-2002. 2010
    ..Emerging therapies are being investigated for their ability to maintain bone health. The findings presented herein highlight the importance of bone-targeted therapies for patients with bone metastases from prostate cancer...
  49. ncbi Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer
    Vincent Fradet
    Département de chirurgie urologie, Centre Hospitalier de l Université de Montreal Montréal, Montreal, Quebec, Canada
    Clin Cancer Res 10:8460-4. 2004
    ....
  50. doi Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer
    Fred Saad
    Centre Hospitalier de i Université de Montréal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urology 76:1175-81. 2010
    ..ZOL has shown significant reductions in SREs and pain compared with placebo in patients with bone metastases from advanced prostate cancer in a randomized placebo-controlled trial...
  51. ncbi Prostate cancer nomograms are superior to neural networks
    Pierre I Karakiewicz
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    Can J Urol 13:18-25. 2006
    ..Several nomograms have been developed to predict PCa related outcomes. Neural networks represent an alternative...
  52. ncbi Therapeutic approach to hormone-refractory prostate cancer
    Fred Saad
    University of Montreal Health Center, CHUM, Montreal, Quebec, Canada
    Can J Urol 13:52-6. 2006
    ..Introducing these effective therapies earlier in high risk patients is also under investigation to further improve outcomes...
  53. pmc Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
    Matthew R Smith
    Matthew R Smith and Philip Saylor, Massachusetts General Hospital Cancer Center, Boston, MA Susan Halabi and Ben Sanford, Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC Charles J Ryan and Eric J Small, University of California at San Francisco, San Francisco, CA Walter Stadler, University of Chicago Nirmala Bhoopalam, Loyola University of Chicago, Chicago, IL Arif Hussain, University of Maryland, Baltimore, MD Nicholas Vogelzang, Nevada Cancer Research Foundation CCOP, Las Vegas, NV Ralph J Hauke, University of Nebraska, Omaha, NE J Paul Monk, Ohio State University, Columbus, OH W Kevin Kelly, Thomas Jefferson University, Philadelphia, PA Michael Morris, Memorial Sloan Kettering Cancer Center, New York, NY Fred Saad, Centre Hospitalier de l Universite de Montreal, Montreal, Canada
    J Clin Oncol 32:1143-50. 2014
    ..This phase III study evaluated the efficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metastatic prostate cancer...
  54. doi Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome
    Faysal A Yafi
    Department of Surgery Urology, McGill University, Montreal, Quebec, Canada
    Urol Oncol 32:31.e17-24. 2014
    ..Our aim was to assess adequacy of renal function and evaluate the role of adjuvant chemotherapy (AC) in patients with UTUC treated by radical nephroureterectomy (RNU) in a universal health care system...
  55. ncbi Early detection of prostate cancer with ultrasound-guided systematic needle biopsy
    Pierre I Karakiewicz
    The University of Montreal Health Center, Montreal, Quebec, Canada
    Can J Urol 12:5-8. 2005
    ..Prostate biopsy strategies have greatly evolved over the past 2 decades...
  56. ncbi uPM3, a new molecular urine test for the detection of prostate cancer
    Yves Fradet
    Universite Laval, Quebec, Quebec, Canada
    Urology 64:311-5; discussion 315-6. 2004
    ..To evaluate, in a multicenter study, the diagnostic performance of a new molecular test uPM3 for detecting prostate cancer cells in urine because of the need for better methods to identify patients at risk of prostate cancer...
  57. doi Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
    Philippe O Gannon
    Research Centre of the Centre Hospitalier de l Université de Montréal CRCHUM, Notre Dame Hospital and Institut du cancer de Montréal 1560 Sherbrooke East, Montreal, Quebec, Canada
    J Immunol Methods 348:9-17. 2009
    ..Our goal was to study the hormonal regulation of immune cell infiltration in prostate cancer patients treated by androgen deprivation therapy (ADT) using an optimized computer-assistance quantification approach...
  58. ncbi Expression and nuclear localization of ErbB3 in prostate cancer
    Ismael Herve Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Quebec, Canada
    Clin Cancer Res 12:2730-7. 2006
    ..The aim of this study was to analyze the expression and localization of ErbB3 in prostate tissues and prostate cancer cell lines...
  59. ncbi Validation of prostate cancer index and SF-12 short forms
    Thierry Lebeau
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    Can J Urol 12:2873-9. 2005
    ....
  60. pmc Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Montreal, QC, Canada
    Urol Oncol 30:369-78. 2012
    ....
  61. doi Preventing bone complications in prostate cancer
    Mohamed Bishr
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    Curr Opin Support Palliat Care 6:299-303. 2012
    ..These events significantly impair the patient's quality of life and place a significant burden on health-care resources...
  62. doi Preservation of bone health in prostate cancer
    Jean Baptiste Lattouf
    Urologic Oncology Division, Centre Hospitalier de l Universite de Montreal, Canada
    Curr Opin Support Palliat Care 1:192-7. 2007
    ..Given the magnitude of bone-related morbidity in advanced prostate cancer, physicians need to be aware of preventive and therapeutic measures, and to be proactive in implementing them...
  63. ncbi Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Université de Montréal and CRCHUM, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Anticancer Agents Med Chem 12:129-36. 2012
    ..This review examines the rationale and emerging evidence supporting the anticancer activity of bisphosphonates, especially ZOL, against prostate and other genitourinary cancers...
  64. ncbi Identification of spermatozoa in archived testicular cancer specimens: implications for bench side sperm retrieval at orchiectomy
    Guila Delouya
    Division of Urology, Department of Radiation Oncology, Centre Hospitalier de l Universite de Montreal, and Department of Surgery, McGill University, Montreal, Quebec, Canada
    Urology 75:1436-40. 2010
    ..To evaluate the patterns of spermatogenesis in the normal testicular parenchyma of primary testicular cancers and estimate the feasibility of sperm retrieval at the time of radical orchiectomy...
  65. doi Maintaining bone health in prostate cancer throughout the disease continuum
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Quebec, Canada
    Semin Oncol 37:S30-7. 2010
    ..This review will examine the breadth of evidence supporting a role for ZOL and emerging therapies in managing patients with PC throughout the disease continuum...
  66. ncbi Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Clin Genitourin Cancer 5:390-6. 2007
    ..We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment...
  67. doi SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer
    Fred Saad
    University of Montreal, CHU Montreal, 1560 Sherbrooke East, Montreal, Quebec, Canada
    Cancer Treat Rev 36:177-84. 2010
    ..Data arising from ongoing and future clinical trials will confirm whether SRC inhibitors provide clinical benefits for patients with advanced disease...
  68. ncbi Role of bisphosphonates in prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Quebec, H2L 4M1, Montreal, Canada
    Eur Urol 45:26-34. 2004
    ..Although the success of current therapeutic options has extended the survival of patients with prostate cancer, they often develop skeletal morbidity from disease and treatment-related effects that undermine skeletal integrity...
  69. ncbi Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors
    Umberto Capitanio
    University of Montreal Health Center, Quebec, Canada
    Urology 74:373-7. 2009
    ..8% for postchemotherapy RPLND) are applicable to institutions at large...
  70. doi Bone complications of androgen deprivation therapy: screening, prevention, and treatment
    Jean Baptiste Lattouf
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Curr Opin Urol 20:247-52. 2010
    ..We herein discuss available strategies to avoid bone loss in this patient population...
  71. doi Bone-marker levels in patients with prostate cancer: potential correlations with outcomes
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Curr Opin Support Palliat Care 4:127-34. 2010
    ..Although bone scans are a reliable means of assessing osteoblastic lesions, tools for monitoring early changes in bone health are lacking. Biochemical markers of bone turnover might fulfill this unmet need...
  72. ncbi Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer
    Fred Saad
    Department of Surgery, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec H2L 4M1, Canada
    Clin Prostate Cancer 4:31-7. 2005
    ..Therefore, zoledronic acid provides long-term continuing clinical benefit for men with prostate cancer and bone metastases and represents a new therapeutic option for this population...
  73. ncbi New research findings on zoledronic acid: survival, pain, and anti-tumour effects
    Fred Saad
    Centre Hospitalier de i Université de Montréal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada PQ H2L 4M1
    Cancer Treat Rev 34:183-92. 2008
    ..To summarize the current evidence for clinical, anti-tumour, and survival benefits from zoledronic acid in patients with genitourinary cancers...
  74. doi Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Quebec, Canada
    Semin Oncol 37:S38-44. 2010
    ..Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life...
  75. ncbi Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Quebec, Canada
    Semin Oncol 29:19-27. 2002
    ..The role of zoledronic acid in the treatment of patients with prostate cancer continues to evolve...
  76. ncbi Zoledronic acid: past, present and future roles in cancer treatment
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Department of Surgery Urologic Oncology, 1560 Rue Sherbrooke East, Montreal, PQ H2L 4M1 Quebec, Canada
    Future Oncol 1:149-59. 2005
    ..Due to its unique pharmacologic profile, zoledronic acid has activity in a variety of clinical settings at low doses and with infrequent intravenous dosing...
  77. doi Cancer treatment-induced bone loss in breast and prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, University of Montreal, Montreal, Quebec, Canada
    J Clin Oncol 26:5465-76. 2008
    ..Bone loss resulting from the treatment of breast and prostate cancer is an emerging problem. Bisphosphonates have a potential role in the prevention of this cancer treatment-induced bone loss (CTIBL)...
  78. ncbi Bone loss in prostate cancer: evaluation, treatment and prevention
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 12:71-6; discussion 99-100. 2005
    ..Bisphosphonates may be beneficial in preventing bone loss and eventually reducing skeletal morbidity due to prostate cancer and ADT...
  79. ncbi Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases
    Fred Saad
    University of Montreal, Montreal, Quebec, Canada
    BJU Int 101:1071-5. 2008
    ..Cumulative evidence supports RANKL inhibition as a therapeutic goal for the treatment and prevention of bone metastases from prostate cancer...
  80. ncbi Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease
    Fred Saad
    Department of Surgical Oncology, Centre Hospitalier de l Université de Montréal Hôpital Notre Dame, Montreal, Quebec, Canada
    Semin Oncol 34:S17-23. 2007
    ..Furthermore, normalization of NTX values correlated with extended survival...
  81. ncbi Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature
    Fred Saad
    University of Montreal, CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 13:16-24. 2006
    ..Is there a known association between duration of wait time beyond the recommended standard and clinical outcome (i.e. recurrence free survival, overall survival)?..
  82. ncbi The role of bisphosphonates in the management of bone metastases in prostate cancer
    Fred Saad
    Department of Urology, University of Montreal CHUM, Montreal, Quebec, Canada
    Can J Urol 11:2376-82. 2004
    ..This article reviews the burden of skeletal complications in patients with prostate cancer, and the evidence for the use of bisphosphonates for the treatment of skeletal morbidity in this patient population...
  83. ncbi Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?
    Jean Baptiste Lattouf
    Department of Urology, Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Que, H2L 4M1, Montreal, Canada
    Eur Urol 43:333-6. 2003
    ..To establish the value of digital rectal exam with respect to PSA in the follow up of radical prostatectomy for prostate adenocarcinoma...
  84. doi Src as a therapeutic target in men with prostate cancer and bone metastases
    Fred Saad
    CHUM, University of Montreal, Montreal, Quebec, Canada
    BJU Int 103:434-40. 2009
    ..This review explores Src inhibition as a strategy for managing bone metastasis in prostate cancer, with a particular focus on targeting the critical osteoclastic response. Other emerging and novel approaches are also considered...
  85. ncbi UPM3: review of a new molecular diagnostic urine test for prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 12:40-3; discussion 99-100. 2005
    ..5 and 4 ng/ml, respectively). This test may become one of the first molecular diagnostic tools to aid in prostate cancer detection...
  86. ncbi Optimizing patient therapy: the role of bone markers?
    Fred Saad
    Universite de Montreal, CHUM Hopital Notre Dame, 1560 Sherbrook E, Montreal, Quebec H2L 4M1, Canada
    Cancer Treat Rev 32:3-6. 2006
    ..This review examines SREs and the burden they impose on patients, the relationship between SREs and bone turnover markers, and the potential role of bone markers in guiding treatment and improving patients' quality of life (QOL)...
  87. ncbi Sunitinib relieves renal cell carcinoma spinal cord compression
    Quoc Dien Trinh
    Department of Urology, Division of Urologic Oncology University of Montreal Health Center, Montreal, Quebec, Canada
    Eur Urol 51:1741-3. 2007
    ..Moreover, it appears that the novel therapies for metastatic RCC may restore quality and quantity of life to many of those, whose disease previously appeared too advanced to treat...
  88. doi Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma
    Philippe O Gannon
    Centre de recherche du CHUM CRCHUM and Institut du cancer de Montréal, Montreal, QC, Canada
    Cancer Immunol Immunother 59:1411-6. 2010
    ..Altogether, these observations support the current understanding of carcinogenesis promoted by chronic inflammation...
  89. ncbi Isolated solitary bony metastasis of a nonseminomatous germ cell tumor
    Abdulhadi Aldejmah
    Department of Surgery, Division of Urology, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Can J Urol 14:3458-60. 2007
    ..He was treated with a left orchiectomy and four cycles of chemotherapy containing bleomycin, etoposide, and cisplatin. He attained complete remission...
  90. ncbi Presence of prostate cancer metastasis correlates with lower lymph node reactivity
    Philippe Olivier Gannon
    Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM and Institut du Cancer de Montréal, Montreal, Quebec, Canada
    Prostate 66:1710-20. 2006
    ..Several reports suggest that the dissemination of neoplastic cells and cancer progression are associated with the generation of an immunosuppressive environment...
  91. ncbi Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Robert E Coleman
    Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, England, UK
    J Clin Oncol 23:4925-35. 2005
    ..These trials provide an opportunity for investigating the correlation between bone metabolism and clinical outcome during bisphosphonate therapy...
  92. ncbi The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion
    J Curtis Nickel
    Department of Urology, Queen s University, Kingston, Ontario, Canada
    Can J Urol 11:2186-93. 2004
    ..Although our perspective is clearly different than our US colleagues, it is likely that the guideline will influence the management of BPH in Canada...
  93. doi Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  94. pmc Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 70:315-9. 2007
    ..Skeletal complications are a major cause of morbidity in men with hormone-refractory metastatic prostate cancer. These analyses were designed to identify the variables associated with a greater risk of skeletal complications...
  95. ncbi Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
    Richard J Cook
    Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
    Clin Cancer Res 12:3361-7. 2006
    ..To evaluate the relative prognostic value for specific markers of osteoblast and osteoclast activity while controlling for previously reported prognostic variables among men with hormone-refractory metastatic prostate cancer...
  96. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    BJU Int 97:1351-2. 2006
  97. ncbi The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate
    Allan Lipton
    Milton S Hershey Medical Center, P O Box 850 H 46, Hershey, PA 17003, USA
    Cancer Invest 20:45-54. 2002
    ..In conclusion, Zol is the first bisphosphonate to demonstrate efficacy in both lytic and blastic disease. The unique properties of this novel agent should be further explored in future clinical trials...
  98. ncbi Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:2918-25. 2005
    ..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
  99. ncbi Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
    Venita Depuy
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Support Care Cancer 15:869-76. 2007
    ..We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs...
  100. ncbi Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Janet E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom
    J Natl Cancer Inst 97:59-69. 2005
    ..We investigated this question in patients with bone metastases secondary to prostate cancer and to non-small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid...
  101. ncbi Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center Durham, North Carolina, USA
    J Urol 171:1537-42. 2004
    ..We estimated the cost-effectiveness of zoledronic acid vs placebo for decreasing skeletal complications in men with prostate cancer...